Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of VELCADE (bortezomib) in patients with MALT lymphoma
2004-004594-29Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- May 2006
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in extranodal marginal zone B-cell lymphoma (EMZL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoints: Overall response rate (ORR) and Safety and toxicity. Started May 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2004-004594-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004594-29.